{
    "clinical_study": {
        "@rank": "110921", 
        "arm_group": [
            {
                "arm_group_label": "ARC-520", 
                "arm_group_type": "Experimental", 
                "description": "Single dose, intravenous administration of ARC-520."
            }, 
            {
                "arm_group_label": "Normal Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single dose, intravenous administration of Normal Saline"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of\n      ARC-520 in normal, adult volunteers."
        }, 
        "brief_title": "Safety and Tolerability Study of ARC-520 in Healthy Volunteers", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Healthy male or female subjects, 18-55 years of age\n\n          -  Be a non-smoker\n\n        Key Exclusion Criteria:\n\n          -  History of clinically relevant medical illnesses that in the Investigator opinion may\n             jeopardize subject safety or interfere with participation in the study, including but\n             not limited to hematological, renal, endocrine, pulmonary, gastrointestinal,\n             cardiovascular, hepatic, psychiatric, neurologic, or allergic disease\n\n          -  Acute signs of hepatitis/other infection (e.g., moderate fever, jaundice, nausea,\n             vomiting, abdominal pain) evident within 4 weeks of screening and/or at the screening\n             examination.\n\n          -  Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days\n             prior to administration of study treatment.\n\n          -  Is sero-positive for HIV, HBV, HCV, and/or a history of delta virus hepatitis.\n\n          -  Currently uses and/or has a history of alcohol and/or drug abuse < 12 months from\n             screening.\n\n          -  Use of investigational agents or devices within 30 days prior to planned study dosing\n             or current participation in an investigational study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01872065", 
            "org_study_id": "Heparc-1001"
        }, 
        "intervention": [
            {
                "arm_group_label": "ARC-520", 
                "intervention_name": "ARC-520", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Normal Saline", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 13, 2014", 
        "location": {
            "contact": {
                "last_name": "Mary Franich", 
                "phone": "1800 243 733"
            }, 
            "facility": {
                "address": {
                    "city": "Melbourne", 
                    "country": "Australia", 
                    "state": "Victoria", 
                    "zip": "3004"
                }, 
                "name": "Nucleus Network Ltd."
            }, 
            "investigator": {
                "last_name": "Jason Lickliter, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 in Normal Adult Volunteers", 
        "overall_contact": {
            "email": "dmartin@arrowres.com", 
            "last_name": "Diamond Martin", 
            "phone": "+1 626 304-3400"
        }, 
        "overall_official": {
            "affiliation": "Nucleus Network Ltd", 
            "last_name": "Jason Lickliter, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Human Research Ethics Committee", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The incidence and frequency of adverse events (AEs), serious adverse events (SAEs), related AEs, related SAEs, and AEs leading to withdrawal, dose modification, or treatment discontinuation will be summarized by dose and treatment group.", 
            "measure": "To determine the incidence and frequency of adverse events as a measure of safety and tolerability of ARC-520", 
            "safety_issue": "Yes", 
            "time_frame": "One month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01872065"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Plasma concentrations following a single dose of ARC-520 at different dose levels will be used to calculate the following ARC-520 pharmacokinetic parameters:  Cmax, tmax, AUC0-24, AUCinf, and t1/2.  Descriptive statistics of pharmacokinetic parameters will include mean, standard deviation, and coefficient of variation.", 
            "measure": "To evaluate the pharmacokinetics of ARC-520 at different dose concentrations", 
            "safety_issue": "No", 
            "time_frame": "2 days"
        }, 
        "source": "Arrowhead Research Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Arrowhead Research Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}